FT 105
Alternative Names: Basulin; FT-105; Long-acting basal insulin - Flamel Technologies; NN 1215Latest Information Update: 01 Feb 2017
At a glance
- Originator Flamel Technologies
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 27 Apr 2012 Discontinued - Phase-I for Diabetes mellitus in Europe (SC)
- 09 Feb 2011 FT 105 is available for licensing as of 18 Oct 2007. http://www.flamel.com
- 09 Feb 2011 No development reported - Phase-I for Diabetes mellitus in Europe (SC)